Abstract: The present invention provides an antibody that binds to an NTCP, capable of inhibiting infection of human hepatocytes with hepatitis B virus (HBV) particles. The present invention also provides an antibody that binds to an NTCP, capable of inhibiting infection of human hepatocytes with hepatitis B virus (HBV) particles, the antibody having a reduced effect on bile acid transport by NTCP.

Abstract: An antibody against spike protein of SARS-CoV-2 is provided, the antibody having a specific heavy chain variable region and a specific light chain variable region, or a fragment of the antibody, the antibody or fragment thereof inhibiting the binding between the spike protein of SARS-CoV-2 and ACE2, the antibody or fragment thereof inhibiting SARS-CoV-2 infection; and a pharmaceutical composition including the antibody or fragment thereof and a pharmaceutically acceptable carrier, the pharmaceutical composition including two or more kinds of the antibody or fragment thereof.

Abstract: Disclosed is an isolated monoclonal antibody against a human Transforming Growth Factor-? (TGF-?) Latency Associated Protein (LAP) degradate, the isolated monoclonal antibody being capable of recognizing an integrin binding site in the human TGF-? LAP degradate.

Abstract: Disclosed is an isolated monoclonal antibody against a human TGF-? LAP degradate, the isolated monoclonal being capable of recognizing an integrin binding site in the human TGF-? LAP degradate.

Abstract: An object is to provide a compound capable of inhibiting activation of TGF-? receptors due to HCV, and a screening method for the compound. It has been found that a HCV-derived NS3 protease binds to type I TGF-? receptor, and this binding results in activation of TGF-? receptors. Moreover, binding sites between the NS3 protease and type I TGF-? receptor were identified, and it has been found that antibodies recognizing these binding sites inhibit activation of TGF-? receptors due to NS3 protease. Furthermore, it has been also found that screening for a compound capable of inhibiting activation of TGF-? receptors can be performed by using the inhibition of the binding between NS3 protease and type I TGF-? receptor or the like as an index.

Abstract: An object is to provide a compound capable of inhibiting activation of TGF-? receptors due to HCV, and a screening method for the compound. It has been found that a HCV-derived NS3 protease binds to type I TGF-? receptor, and this binding results in activation of TGF-? receptors. Moreover, binding sites between the NS3 protease and type I TGF-? receptor were identified, and it has been found that antibodies recognizing these binding sites inhibit activation of TGF-? receptors due to NS3 protease. Furthermore, it has been also found that screening for a compound capable of inhibiting activation of TGF-? receptors can be performed by using the inhibition of the binding between NS3 protease and type I TGF-? receptor or the like as an index.

Abstract: This invention provides a process for producing an isotope-labeled protein used as a sample for protein 3D structural analysis via NMR in a cost-effective manner within a short period of time. In this process, a protein is synthesized using, as a substrate, an amino acid mixture that contains a maximum of 19 different types of amino acids selected from the group consisting of alanine, arginine, aspartic acid, cysteine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, asparagine, and glutamine in a cell-free protein synthesis system.